A PYMNTS Company

US: Endo joins FTC’s “back-door” challenge

By  |  January 9, 2018

On Friday, January 5, the Federal Trade Commission gave Endo Pharmaceuticals the go-ahead to weigh in on the government’s administrative proceeding against Impax Laboratories. The case alleges that a 2010 settlement between the companies allowing Endo to introduce a generic version of Impax’s Opana ER had no pro-competitive justifications.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Endo will be allowed to submit a brief opposing the government’s request for relief in its action against Impax that could potentially affect or nullify a second settlement reached between the two pharmaceutical companies in 2017.

    The original complaint in 2012, accused Endo in 2012 of working a deal in which they compensated Watson Laboratories “hundreds of millions of dollars” to hold off a generic version of Endo’s Lidoderm patch.  It also accused Endo of paying Impax $112 million in 2010 to hold off releasing an authorized generic version of Endo’s painkiller Opana. The FTC alleged Endo’s financial gain by giving it time to transition patients to a new formulation of Opana ER, “thereby maintaining its monopoly power.”

    Full Content: Federal Trade Commission and Global Competition Review

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.